Browse LAMA3

Summary
SymbolLAMA3
Namelaminin, alpha 3
Aliases nicein-150kDa; kalinin-165kDa; BM600-150kDa; epiligrin; LAMNA; laminin, alpha 3 (nicein (150kD), kalinin (16 ......
Chromosomal Location18q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix, basement membrane. Note=Major component.
Domain PF00052 Laminin B (Domain IV)
PF00053 Laminin EGF domain
PF02210 Laminin G domain
PF06008 Laminin Domain I
PF06009 Laminin Domain II
PF00055 Laminin N-terminal (Domain VI)
Function

Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components.; FUNCTION: Laminin-5 is thought to be involved in (1) cell adhesion via integrin alpha-3/beta-1 in focal adhesion and integrin alpha-6/beta-4 in hemidesmosomes, (2) signal transduction via tyrosine phosphorylation of pp125-FAK and p80, (3) differentiation of keratinocytes.

> Gene Ontology
 
Biological Process GO:0001704 formation of primary germ layer
GO:0001706 endoderm formation
GO:0007044 cell-substrate junction assembly
GO:0007369 gastrulation
GO:0007492 endoderm development
GO:0008544 epidermis development
GO:0022617 extracellular matrix disassembly
GO:0030198 extracellular matrix organization
GO:0031581 hemidesmosome assembly
GO:0034329 cell junction assembly
GO:0034330 cell junction organization
GO:0035987 endodermal cell differentiation
GO:0043062 extracellular structure organization
GO:0045995 regulation of embryonic development
Molecular Function -
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005604 basement membrane
GO:0005605 basal lamina
GO:0005610 laminin-5 complex
GO:0043256 laminin complex
GO:0044420 extracellular matrix component
> KEGG and Reactome Pathway
 
KEGG hsa04151 PI3K-Akt signaling pathway
hsa04510 Focal adhesion
hsa04512 ECM-receptor interaction
hsa01100 Metabolic pathways
Reactome R-HSA-2214320: Anchoring fibril formation
R-HSA-2022090: Assembly of collagen fibrils and other multimeric structures
R-HSA-446728: Cell junction organization
R-HSA-1500931: Cell-Cell communication
R-HSA-1474290: Collagen formation
R-HSA-1474228: Degradation of the extracellular matrix
R-HSA-3000178: ECM proteoglycans
R-HSA-1474244: Extracellular matrix organization
R-HSA-3000157: Laminin interactions
R-HSA-8874081: MET activates PTK2 signaling
R-HSA-8875878: MET promotes cell motility
R-HSA-3000171: Non-integrin membrane-ECM interactions
R-HSA-162582: Signal Transduction
R-HSA-6806834: Signaling by MET
R-HSA-446107: Type I hemidesmosome assembly
Summary
SymbolLAMA3
Namelaminin, alpha 3
Aliases nicein-150kDa; kalinin-165kDa; BM600-150kDa; epiligrin; LAMNA; laminin, alpha 3 (nicein (150kD), kalinin (16 ......
Chromosomal Location18q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LAMA3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolLAMA3
Namelaminin, alpha 3
Aliases nicein-150kDa; kalinin-165kDa; BM600-150kDa; epiligrin; LAMNA; laminin, alpha 3 (nicein (150kD), kalinin (16 ......
Chromosomal Location18q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LAMA3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLAMA3
Namelaminin, alpha 3
Aliases nicein-150kDa; kalinin-165kDa; BM600-150kDa; epiligrin; LAMNA; laminin, alpha 3 (nicein (150kD), kalinin (16 ......
Chromosomal Location18q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LAMA3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0430.928
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1650.835
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0350.957
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2930.553
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0740.975
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.7560.798
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1010.873
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2890.799
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0340.976
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0950.939
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1840.914
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4910.0369
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LAMA3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277325.98.217.70.0389
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275925.910.215.70.101
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211728.611.816.80.257
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8637.5037.50.209
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.118.24.91
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.218.83.41
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 475014.335.70.491
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.97.40.51
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolLAMA3
Namelaminin, alpha 3
Aliases nicein-150kDa; kalinin-165kDa; BM600-150kDa; epiligrin; LAMNA; laminin, alpha 3 (nicein (150kD), kalinin (16 ......
Chromosomal Location18q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LAMA3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLAMA3
Namelaminin, alpha 3
Aliases nicein-150kDa; kalinin-165kDa; BM600-150kDa; epiligrin; LAMNA; laminin, alpha 3 (nicein (150kD), kalinin (16 ......
Chromosomal Location18q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LAMA3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LAMA3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLAMA3
Namelaminin, alpha 3
Aliases nicein-150kDa; kalinin-165kDa; BM600-150kDa; epiligrin; LAMNA; laminin, alpha 3 (nicein (150kD), kalinin (16 ......
Chromosomal Location18q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LAMA3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLAMA3
Namelaminin, alpha 3
Aliases nicein-150kDa; kalinin-165kDa; BM600-150kDa; epiligrin; LAMNA; laminin, alpha 3 (nicein (150kD), kalinin (16 ......
Chromosomal Location18q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LAMA3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLAMA3
Namelaminin, alpha 3
Aliases nicein-150kDa; kalinin-165kDa; BM600-150kDa; epiligrin; LAMNA; laminin, alpha 3 (nicein (150kD), kalinin (16 ......
Chromosomal Location18q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LAMA3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLAMA3
Namelaminin, alpha 3
Aliases nicein-150kDa; kalinin-165kDa; BM600-150kDa; epiligrin; LAMNA; laminin, alpha 3 (nicein (150kD), kalinin (16 ......
Chromosomal Location18q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LAMA3 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting LAMA3.
ID Name Drug Type Targets #Targets
DB06245LanoteplaseBiotechANXA2, CALR, CANX, CLEC3B, F10, FGA, FN1, KLK1, KRT8, LAMA1, LAMA3 ......17